Литература

Глава тринадцатая из книги "Руководство по лечению лимфомы Ходжкина, 2021 г."
Руководство для врачей
Автор: д.м.н., проф. Е.А. Демина

⇐ Назад к содержанию книги

Список литературы / References

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009;20(3). Приложение 1.
2. Клиническая онкогематология. Руководство для врачей. Под ред. проф. Волковой М.А. Издание 2-е. М.: Медицина, 2007:79–723.
3. Lister T.A., Crowther D., Sutcliffe S.B. et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630–1636.
4. Демина Е.А., Тумян Г.С., Унукова Е.Н. и соавт. Современные возможности лечения первичных больных лимфомой Ходжкина и причины неудач лечения. Онкогематология. 2007;2:24–30.
5. Engert A., Franklin J., Eich H.T. et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–3502. doi: 10.1200/jco.2006.07.0482.
6. Engert A., Plutschow A., Eich H.T. et al. Reduced treatment intensity in patients with early stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–652.
7. Ткачев С.И., Демина Е.А., Трофимова О.П., Сахаровская В.Г. Современное лечение больных с ранними стадиями лимфомы Ходжкина. Вопросы онкологии. 2007;53(1):114–117.
8. Morschhauser F., Brice P., Fermé C. et al. Risk Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin’s Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group. JCO. 2008:5980–5987.
9. Sieniawski M., Franklin J., Nogova L. et al. Outcome of Patients Experiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemo therapy and Radiotherapy for Early-Stage Favorable Hodgkin’s Lymphoma. JCO. 2007;25:2000–2005.
10. Josting A., Nogová L., Franklin J. et al. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. JCO. 2005;23:1522–1529.
11. Sureda A., Robinson S., Canals S. et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JCO. 2008;26:455–462.
12. Gallamini A., Hutchings M., Rigacci L et al. Early Interim 2-[18F]Fluoro-2-Deoxy-DGlucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin’s Lymphoma: A Report From a Joint ItalianDanish Study. JCO. 2007;25:3746–3752.
13. Cheson B.D., Pfistner B., Juweid V.E. et al. Revised Response Criteria for Malignant Lymphoma. JCO. 2007;25:579–586.
14. Federico M., Luminari S., Iannitto E. et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin’s Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. JCO. 2009;27:805–811.
15. Behringer K., Thielen I., Mueller H. et al. Fertility and gonadal function in female survivors aft er treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol. 2012;23(7):1818–1825.
16. Пылова И.В., Шмаков Р.Г., Демина Е.А. и соавт. Эффективность защиты яичников при проведении химиотерапии у женщин с лимфомой Ходжкина. Акушерство и гинекология. 2011;7(1):40–45.
17. Engert A., Haverkamp H., Kobe C. et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial):a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
18. Engert A., Bredenfeld H., Döhner H. et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica. 2006;91(4):546–549.
19. Sieber M., Bredenfeld H., Josting A. et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group. JCO. 2003;21(9):1734–1739.
20. Ferme C., Eghbali H., Meerwaldt J.H. et al. Chemotherapy plus involved-fi eld radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916–1927.
21. Borchmann P., Engert A., Pluetschow A. et al. Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL):An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood (ASH Annual Meeting Abstracts). 2008;112:367.
22. Ekstrand B., Lucas L., Horwitz S. et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285–4289.
23. Schulz H., Rehwald U., Morschhauser F. et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109–111.
24. Kobe C., Dietlein M., Franklin J. et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989–3994.
25. Hutchings M., Loft A., Hansen M. et al. FDGPET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52–59.
26. Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071.
27. Peggs K.S., Hunter A., Chopra R. et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma eff ect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934–1941.
28. Santoro A., Magagnoli M., Spina M. et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92:35–41.
29. Behringer K., Thielen I., Mueller H. et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol. 2012;23(7):1818–1825.
30. Eichenauer D.A., Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? Leukemia & Lymphoma. 2009;50(11):1733–1734.
31. Meyer R.M., Gospodarowicz M.K., Connors J.M. et al. ABVD Alone versus Radiation Based Therapy in Limited-Stage Hodgkin’s Lymphoma. N Engl J Med. 2012;366:399–408.
32. Nogova L., Reineke T., Brillant C. et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26:434–439.
33. Jackson C., Sirohi B., Cunningham D. et al. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. Annals of Oncology. 2010;21:2061–2068.
34. Advani R.H., Horning S.J., Hoppe R.T. et al. Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. ASH Annual Meeting Abstracts. 2011;118:2686.
35. Swerdlow A.J., Higgins C.D., Smith P. et al. Second cancer risk after chemotherapy for Hodgkin’s lymphoma: a collaborative British cohort study. J Clin Oncol. 2011;29:4096–4104.
36. El-Galaly T., Mylam K.J., Brown P. et al. PET/ CT surveillance in patients with Hodgkin lymphoma in fi rst remission is associated with low positive predictive value and high costs. Haematologica. 2012;97:931–936.
37. Puig N., Pintilie M., Seshadri T. et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma. Haematologica. 2010;95:1496–1502. doi: 10.3324/haematol.2009.019943.
38. Connors J.M. Positron Emission Tomography in the Management of Hodgkin Lymphoma Hematology. 2011:317–322.
39. Younes A., Gopal A.K., Smith S.E. et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol. 2012;30:2183–2189.
40. Jagadeesh D., Diefenbach C., Evens A. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hemat Oncol. 2013;31(suppl. 1):69–75.
41. Engert A., Horning S. Hodgkin Lymphoma. A comprehensive update on diagnostics and clinics. 2011:381.
42. Boll B., Bredenfeld H., Gorgen H. et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicine, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011;118:6292–6298.
43. Klimm B., Diehl V., Pfistner B., Engert A. Current treatment strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol. 2005;66:125–134.
44. Fiandra C., Filippi A.R., Catuzzo P. et al. Diff erent IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s Lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol. 2012;7:186.
45. Sickinger M.T., von Tresckow B., Kobe C., Engert A., Borchmann P., Skoetz N. Cochrane Database of Systematic Reviews. 2015;1.
46. Von Tresckow B., Plϋtschow А., Fuchs М. et al. Dose-Intensification in Early Unfavorable Hodgkin’s Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol. 2012;30:907–913.
47. Younes A. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–1294.
48. Klimm B., Goergen H., Fuchs M. et al. Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: an analysis of international staging definitions B. Annals of Oncology. 2013;24:3070–3076. doi: 10.1093/annonc/mdt413.
49. Santoro A., Mazza R., Pulsoni A. et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016;34:3293– 3299. doi: 10.1200/JCO.2016.66.4466.
50. Bartlett N.L., Chen R., Fanale M.A. et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;19(7):24. doi: 10.1186/1756-8722-7-24.
51. Gallamini A., Patti C., Viviani S. et al. Early chemotherapy intensification with BEACOPP in advanced stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. British Journal of Haematology. 2011;152(5):551–560. doi: 10.1111/j.1365-2141.2010.08485.x.
52. Straus D.J., Pitcher B., Kostakoglu L. et al. Initial Results of US Intergroup Trial of ResponseAdapted Chemotherapy or Chemotherapy/ Radiation Therapy Based on PET for Non Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). Blood. 2015;126(23):578. doi: 10.1182/blood.V126.23.578.578.
53. Press O.W., LeBlanc M., Rimsza L.M. et al. A phase II trial of response-adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US Intergroup S0816. Hematol Oncol. 2013;31(1):137. Abstract 124.
54. Капланов К.Д., Клиточенко Т.Ю., Шипаева А.Л., Широкова М.Н. и соавт. Программа IVDG – возможный выбор первой линии терапии лимфомы Ходжкина у пациентов пожилого возраста с сопутствующими сердечно-сосудистыми и легочными заболеваниями. Клиническая онкогематология. 2017;3:358–365.
55. Kaplanov К., Klitochenko Т., Shipaeva А. et al. Combination of idarubicin, vinblastine, dacarbazine, and gemcitabine (IVDG) as therapy for elderly patients with Hodgkin lymphoma with cardiac and pulmonary comorbidity. Hematological Oncology. 2017;35(2):317. doi: 10.1002/hon.2439_5.
56. Perrot A., Monjanel H., Bouabdallah R. et al. Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101(4):466–473. doi: 10.3324/haematol.2015.134213.
57. Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classifi cation. JCO. 2014;32:3059–3067. doi: 10.1200/JCO.2013.54.8800.
58. Roemer M.G., Advani R.H., Ligon A.H. et al. PD-L1 and PD-L2 Genetic Alterations Defi ne Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016;34(23):2690–2697. doi: 10.1200/JCO.2016.66.4482.
59. Gallamini А., Hutchings М., Rigacci L. et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin’s Lymphoma: A Report From a Joint ItalianDanish Study. J Clin Oncol. 2007;25:3746–3752. doi: 10.1200/JCO.2007.11.6525.
60. Gallamini A., Barrington S., Biggi A. et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville fi vepoint scale. Haematologica. 2014;99(6):1107–1113.
61. Hutchings M. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Hematol Oncol Clin N Am. 2014;28(1):87–103.
62. Radford J., Barrington S., Counsell N. et al. Involved fi eld radiotherapy vs no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a ‘negative’ PET scan after 3 cycles ABVD: results of the UK NCRI RAPID trial. Blood. 2012;120(21):547.
63. Cheson B., Ansell S., Schwartz L. et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128(21):2489–2496. doi: 10.1182/blood-2016-05-718528.
64. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition. Edited by Swerdlow S.H., Campo E., Harris N.L. et al. International Agency for Research on Cancer Lyon, 2017.
65. Saarinen S., Pukkala E., Vahteristo P. et al. High Familial Risk in Nodular Lymphocyte Predominant Hodgkin Lymphoma. JCO. 2013;31(7):938–943.
66. Nogova L., Reineke T., Brillant C. et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26:434–439.
67. Hasenclever D., Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339:1506–1514.
68. Sieniawski M., Franklin J., Nogova L. et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin’s lymphoma. J Clin Oncol. 2007;25:2000–2005.
69. Sasse S., Brockelmann P.J., Goergen H. Long Term Follow-Up of Contemporary Treatment in EarlyStage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 201735:1999–2007.
70. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Руководство по лечению лимфомы Ходжкина. Под редакцией проф. И.В. Поддубной и проф. В.Г. Савченко. М., 2018.
71. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2018.
72. Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14(10):943–952.
73. Engert A., Diehl V., Franklin J. et al. Escalated Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin’s Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study. J Clin Oncol. 2009;27:4548–4554.
74. Borchmann P., Goergen H., Kobe C. et al. EBEACOPP with or without rituximab in interim-PET-positive advanced-stage Hodgkin lymphoma updated results of the international, randomized phase 3 GHSG HD18 trail. Hem Oncol. 2017;35(2):65. Abstrakt 53.
75. Engert A., Haverkamp H., Kobe C., Markova J. et al. Reduced-intensity chemotherapy and PETguided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial):a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–1799.
76. Fanale M.A., Cheah C.Y., Rich A. et al. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017;130(4):472–477. doi: 10.1182/blood-2017-02-766121.
77. Longo D.L., Duffey P.L., Young R.C. et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. JCO. 1992;10:210–218. doi: 10.1200/JCO.1992.10.2.210.
78. Puig N., Pintilie M., Seshadri T. et al. Different Response To Salvage Chemotherapy But Similar Post-Transplant Outcomes In Patients With Relapsed And Refractory Hodgkin’s Lymphoma. Haematologica. 2010;95:1496–1502. doi: 10.3324/haematol.2009.019943.
79. Thomson K.J., Kayani I., Ardeshna K. et al. A response-adjusted PET-based trans plantation strategy in primary resistant and relapsed Hodgkin Lymphoma. Leukemia. 2013;27:1419–1422.
80. Chen R., Gopal A.K., Smith S.E. et al. Five-year survival data demonstrating durable responses from a pivotal phase 2 study of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma [ASH abstract 2736]. Blood. 2015;126(suppl 23).
81. Moskowitz C.H., Walewski J., Nademanee A. et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. doi: 10.1182/blood-2018-07-861641.
82. Walewski J.A., Nademanee A., Masszi T. et al. Multivariate analisis of PFS from the AETHERA trail: a phase 3 study of brentuximab vedotin consolidation after autologous stem cell transplant for HL. ASCO. June 2015, Chicago Illinoice USA. Abstr 8519.
83. Batlevi C.L., Younes A. Novel therapy for Hodgkin lymphoma. Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY. doi: 10.1182/asheducation-2013.1.394.
84. Connors J.M., Jurczak W., Straus J. et al. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018;378:331–344. doi: 10.1056/NEJMoa1708984.
85. Ansell S.M. Nivolumab in the Treatment of Hodgkin Lymphoma Clin Cancer Res. 2017;23(7):1623–1626. doi: 10.1158/1078-0432.CCR-16-1387.
86. Демина Е.А. Блокада PD1 пути ниволумабом – новая возможность иммунотерапии классической лимфомы Ходжкина. Клиническая онкогематология. 2018;11(3):213–218.
87. Ansell S.M., Lesokhin A.M., Borrello I. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–319. doi: 10.1056/NEJMoa1411087.
88. Devillier R., Coso D., Castagna L. et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy. Haematologica. 2012;97(7):1073–1079. doi: 10.3324/haematol.2011.056051.
89. Barry R.M., Diamond H.D., Craver L.F. Influence of pregnancy on the course of Hodgkin; s disease. Am J Obst & Gynec. 1962;84(4):445–454.
90. Пылова И.В., Демина Е.А., Шмаков Р.Г., Перилова Е.Е. Влияние беременности и родов на течение лимфомы Ходжкина. Гематология и трансфузиология. 2006;51(5):8–13.
91. Aviles A., Neri N., Nambo M.J. Hematological malignancies and pregnancy: Treat or no treat during fi rst trimester. Int J Cancer. 2012;131:2678–2683.
doi: 10.1002/ijc.27560.
92. Santoro A., Mazza R., Pulsoni A. et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016;34:3293– 3299. doi: 10.1200/JCO.2016.66.4466.
93. Gallamini A., Patti C., Viviani S. Early chemotherapy intensication with BEACOPP in advanced stage Hodgkin lymphoma patients with a interim PET positive after two ABVD courses. BJH. 2011;152(5):511–560.
94. Roemer M.G., Advani R.H., Ligon A.H. et al. PD-L1 and PD-L2 Genetic Alterations Defi ne Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016;34(23):264–267.
95. Eichenauer D.A., Plütschow A., Kreissl S. et al. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin’s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. Lancet Oncology. 2017;18(2):1680–1687. Published Online November 10, 2017. doi: 10.1016/S1470-2045(17)30696-4.
96. Fessas P., Lee H. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors Nivolumab and pembrolizumab. Seminars in Oncology. 2017;44:136–140.
97. Chen R., Zinzani P.L., Fanale M.A. et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35:2125–2132. doi: 10.1200/JCO.2016.72.1316.
98. Демина Е.А. Современная терапия первичных больных лимфомой Ходжкина. Автореферат дисс. … д.м.н. М., 2006.
99. Katz J., Janik J.A., Yones A. Brentuximab vedotin (SGN-35). Clin Cancer Res. 2011;17:6428–6436. doi: 10.1158/1078-0432.CCR-11-0488.
100. Демина Е.А., Леонтьева А.А., Тумян Г.С. с соавт. Значение позитронно-эмиссионной томографии в оптимизации терапии распространенных стадий лимфомы Ходжкина с использованием интенсивной программы ЕАСОРР-14. Клиническая онкогематология. 2017;10(2):150–157.
101. Демина Е.А., Леонтьева А.А., Тумян Г.С. с соавт. Оптимизация терапии первой линии у пациентов с распространенными стадиями лимфомы Ходжкина. Эффективность и токсичность интенсивной схемы ЕАСОРР-14 (опыт ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России). Клиническая онкогематология. 2017;10(4):443–452.
102. Borchmann P., Goergen H., Kobe C. et al. PETguided treatment in patients with advanced stage Hodgkin’s lymphoma (HD18):final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790–2802. Published Online October 20, 2017. doi: 10.1016/S0140-6736(17)32134-7.
103. Гурцевич В.Э., Демина Е.А., Сенюта Н.Б. с соавт. Вирус Эпштейна – Барр у больных классической лимфомой Ходжкина. Клиническая онкогематология. 2018;11(2):160–166.
104. Fuchs M., Goergen H., Kobe C. et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835–2845. doi: 10.1200/JCO.19.00964.
105. Fuchs M., Plütschow A., Kobe C. et al. Prognostic Impact of PET after 2 Cycles of Escalated Beacopp Plus 2 Cycles of ABVD on Progression Free Survival in Early Unfavourable Hodgkin Lymphoma within the Phase 3 GHSG HD17 Trial. ASH 62th, 2020, poster 2065.
106. Johnson P., Federico M., Kirkwood A. et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374:2419–2429. doi: 10.1056/NEJMoa1510093.
107. Borchmann P. Positron Emission Tomography Guided Omission of Radiotherapy in Early-Stage Unfavorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD17 Trial by the GHSG. The Abstract Book of the 25th Congress of the European Hematology Association. HemaSphere, 2020;4:S1, Abstract Book, p1, abstr S101. doi: 10.1097/HS9.0000000000000404.
108. Fuchs M., Plütschow A., Kobe C. et al. Prognostic Impact of PET after 2 Cycles of Escalated Beacopp Plus 2 Cycles of ABVD on Progression Free Survival in Early Unfavourable Hodgkin Lymphoma within the Phase 3 GHSG HD17 Trial. ASH 62th, 2020, poster 2065.
109. Casasnovas R.-O., Bouabdallah R., Brice P. et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011):a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20:202–215. doi: 10.1016/S1470-2045(18)30784-8.
110. Casasnovas O., Racape J., Dechene J. et al. PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study. ASH 62th, 2020, abstr 475.
111. Tumyan G., Demina Е., Paramonova Е. et al. EA(50)COPP-14 ± Radiotherapy is an Effective Regimen fOR Patients With Advanced Stages of Classical Hodgkin Lymphoma: Results of the Modified Protocol «Hlmoscow 1-3» The Abstract Book of the 25th Congress of the European Hematology Association. HemaSphere, 2020;4:S1, Abstract Book, p. 527, poster EP1137. doi: 10.1097/HS9.0000000000000404.
112. Straus D.J., Dlugosz-Danecka M., Connors J.M. et al. Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. ASH 62th, 2020, poster 2973.
113. Демина Е.А., Тумян Г.С., Моисеева Т.Н. c соавт. Лимфома Ходжкина. Клинические рекомендации. Современная онкология. 2020;22(2):6–20. doi: 10.26442/18151434.2020.2.200132.
114. Goldie J.H., Coldman A.J. Analyzing the patterns of treatment failure. Journal of Clinical Oncology. 1986;4(6):825–826. doi: 10.1200/JCO.1986.4.6.825.
115. Ferhanoglu B., Kim Tae Min, Karduss A. et al. Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma. ASH 62th, 2020, poster 2979.
116. Kersten M.J., Driessen J., Zijlstra J.M. et al. Combining brentuximab vedotin with dexamethasone, highdose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Haematologica Early view Apr 9, 2020. doi: 10.3324/haematol.2019.243238.
117. Lynch R.C., Cassaday R.D., Smith S.D. et al. Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study. ASH 62th, 2020, poster 2964.
118. Armand P., Engert A., Younes A. et al. Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Phase 2 Single-Arm CheckMate 205 Study. Poster presentation at ASH 2018. Abstract 2897.
119. Ramchandren R., Domingo-Domenech E., Rueda A. et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019;37:1997–2007. doi: 10.1200/JCO.19.00315.
120. Ansell S., Ramchandren R., Domingo‐Domènech E. et al. Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced‐Stage Classical Hodgkin Lymphoma: Checkmate 205 Cohort D 2‐Year Follow‐Up. 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18-22 June, 2019. Hematol Oncol. 2019;37(S2):146–147. doi: 10.1002/hon.104_2629.
121. Carreau N.A., Pail O., Armand P. et al. Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy. The Oncologist. 2020;25:1–8. doi: 10.1634/theoncologist.2020-0167.
122. Kuruvilla J., Ramchandren R., Santoro A. et al. KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). ASCO 2020, abstract 8005. Journal of Clinical Oncology. Published online before print May 25, 2020. doi: 10.1200/JCO.2020.38.15_suppl.8005.
123. Kuruvilla J., Ramchandren R., Santoro A. et al. Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL):Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. ASH 62th, 2020, poster 1158.
124. Zinzani P.L., Ramchandren R., Santoro A. et al. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study. ASH 62th, 2020, abstr 374.
125. FDA Approves Expanded Indication for Merck’s Keytruda (pembrolizumab) in Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL).
126. Herrera A.F., Chen R., Palmer J. et al. PET-adapted Nivolumab +/ICE (NICE) as First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. 15-ICML, June 10-20, 2019, poster 238P. doi: 10.3252/pso.eu.15ICML.2019.
127. Moskowitz A.J., Shah G., Schöder H. et al. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. ASH 62th, 2020, poster 470.
128. Herrera A.F., Moskowitz A.J., Bartlett N.L. et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194. doi: 10.1182/blood-2017-10-811224.
129. Manson G., Brice P., Herbaux C. et al. Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation. Haematologica. 2020;105(11):2664–2466. doi: 10.3324/haematol.2019.242529.
130. Yasenchak C.A., Bordoni R., Patel-Donnelly D. et al. Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients. ASH 62th, 2020, abstr 471.
131. Maraldo M.V., Kicinski M., van der Kaaij M.A. E. et al. Returning to School or Work After Hodgkin Lymphoma: An Eortc-Lysa Cross-Sectional Study. HemaSphere Abstract Book for the 11th International Symposium on Hodgkin Lymphoma. Cologne, Germany. October 27-29 2018, p16, abstr P034 (0021).
132. Eichenauer DA, Engert A. How I Treat Nodular Lymphocyte-predominant Hodgkin Lymphoma. Blood. 2020;136(26):2987-2993. doi: 10.1182/blood.2019004044.